BioCentury
ARTICLE | Finance

Lion's share of the work

Why Aslan thinks its BMS deal validates its model ahead of a Taiwanese IPO

August 15, 2016 7:00 AM UTC

Aslan Pharmaceuticals Pte. Ltd.'s 2011 deal with Bristol-Myers Squibb Co. (NYSE:BMY) was atypical in terms of stage and scope, but the biotech thinks the partnership validates its business model of in-licensing cancer compounds, doing development and then re-partnering the asset. The validation is nice to have as Aslan starts to line up for a Taiwanese IPO.

In 2011, BMS granted Aslan Asian rights to ASLAN002 (BMS-777607), a small molecule dual inhibitor of c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene) and macrophage stimulating 1 receptor c-Met-related tyrosine kinase (MST1R; RON; CD136). The biotech then designed and completed a Phase I program...